-
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 8, 2024
-
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
-
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
-
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
-
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
-
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 8, 2024
-
XOMA Announces Stock Repurchase Program of up to $50 Million
January 2, 2024
-
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023
-
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023
-
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 7, 2023
-
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023
-
XOMA Declares Quarterly Preferred Stock Dividends
September 25, 2023
-
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 6, 2023
-
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
August 8, 2023
-
XOMA Added to the Russell 2000® and Russell 3000® Indexes
June 23, 2023